NasdaqCM - Delayed Quote USD

Aptose Biosciences Inc. (APTO)

1.1600 -0.0600 (-4.92%)
At close: April 25 at 4:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
52,356.0000
52,356.0000
42,602.0000
65,447.0000
55,768.0000
Operating Income
-52,356.0000
-52,356.0000
-42,602.0000
-65,447.0000
-55,768.0000
Net Non Operating Interest Income Expense
1,151.0000
1,151.0000
788.0000
94.0000
522.0000
Other Income Expense
-2.0000
-2.0000
-9.0000
-1.0000
8.0000
Pretax Income
-51,207.0000
-51,207.0000
-41,823.0000
-65,354.0000
-55,238.0000
Net Income Common Stockholders
-51,207.0000
-51,207.0000
-41,823.0000
-65,354.0000
-55,238.0000
Diluted NI Available to Com Stockholders
-51,207.0000
-51,207.0000
-41,823.0000
-65,354.0000
-55,238.0000
Basic EPS
-7.58
-7.58
-6.80
-10.95
-10.05
Diluted EPS
-7.58
-7.58
-6.80
-10.95
-10.05
Basic Average Shares
6,755.0000
6,755.0000
6,151.0000
5,939.0660
5,455.8000
Diluted Average Shares
6,755.0000
6,755.0000
6,151.0000
5,939.0660
5,455.8000
Total Expenses
52,356.0000
52,356.0000
42,602.0000
65,447.0000
55,768.0000
Net Income from Continuing & Discontinued Operation
-51,207.0000
-51,207.0000
-41,823.0000
-65,354.0000
-55,238.0000
Normalized Income
-51,205.0000
-51,205.0000
-41,814.0000
-65,353.0000
-55,246.0000
Interest Income
1,151.0000
1,151.0000
788.0000
94.0000
522.0000
Net Interest Income
1,151.0000
1,151.0000
788.0000
94.0000
522.0000
EBIT
-52,356.0000
-52,356.0000
-42,602.0000
-65,447.0000
-55,768.0000
EBITDA
-51,890.0000
-51,890.0000
-42,074.0000
-64,825.0000
-55,154.0000
Reconciled Depreciation
466.0000
466.0000
528.0000
622.0000
614.0000
Net Income from Continuing Operation Net Minority Interest
-51,207.0000
-51,207.0000
-41,823.0000
-65,354.0000
-55,238.0000
Total Unusual Items Excluding Goodwill
-2.0000
-2.0000
-9.0000
-1.0000
8.0000
Total Unusual Items
-2.0000
-2.0000
-9.0000
-1.0000
8.0000
Normalized EBITDA
-51,888.0000
-51,888.0000
-42,065.0000
-64,824.0000
-55,162.0000
12/31/2020 - 3/16/1992

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

TFFP TFF Pharmaceuticals, Inc.
3.0500
+3.39%
 
CGTX Cognition Therapeutics, Inc.
1.9300
-3.02%
 
ALZN Alzamend Neuro, Inc.
0.7000
-1.30%
 
SXTP 60 Degrees Pharmaceuticals, Inc.
0.2336
-3.59%
 
CUE Cue Biopharma, Inc.
1.4100
-0.70%
 
DMAC DiaMedica Therapeutics Inc.
2.5300
+3.27%
 
CALC CalciMedica, Inc.
5.29
-2.94%
 
ZNTL Zentalis Pharmaceuticals, Inc.
10.99
-6.67%
 
RNXT RenovoRx, Inc.
1.2100
-1.63%
 
ONCT Oncternal Therapeutics, Inc.
8.25
-4.18%